New Results for Patisiran at PNS 2021

New Results for Patisiran at PNS 2021

Positive results from a Phase 3b open-label study of patisiran in hereditary ATTR amyloidosis patients with polyneuropathy progression after receiving an orthotopic liver transplant were presented at the Peripheral Nerve Society’s 2021 Annual Meeting.

Read our press release
View the presentation



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.